GlassScriptPhysician profile
Omni R Mccluney
NPI 1689005860
$17,638.22
in general payments reported to CMS, 2019-2025
24 companies · $3,454 in 2025
The $3,454 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $789 · 2022: $2,030 · 2023: $2,591 · 2024: $8,775 · 2025: $3,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,090 · Travel and Lodging: $3,325 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,940 · Consulting Fee: $900 · Education: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,090.28 |
| Travel and Lodging | $3,324.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,940.00 |
| Consulting Fee | $900.00 |
| Education | $564.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $7,504.26 | 2022-2025 | |
| Abbvie INC. | $2,655.74 | 2021-2025 | |
| Genzyme Corporation | $1,143.38 | 2021-2025 | |
| Eli Lilly and Company | $900.00 | 2025 | Olumiant |
| Incyte Corporation | $708.84 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $690.75 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $678.31 | 2022-2025 | Tremfya |
| Amgen INC. | $637.88 | 2022-2023 | Otezla |
| Leo Pharma INC. | $519.12 | 2022-2024 | Adbry |
| Galderma Laboratories, L.P. | $414.48 | 2022-2025 | Nemluvio, Twyneo, Epsolay |
| Sanofi-Aventis U.S. LLC | $366.99 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $285.31 | 2024 | Dupixent |
| Lilly USA, LLC | $279.17 | 2023-2025 | Ebglyss, Olumiant, Taltz |
| Journey Medical Corporation | $237.62 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $196.81 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $134.07 | 2023-2025 | Absorica Ld, Winlevi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.30 | 2024 | Spevigo |
| Paratek Pharmaceuticals, INC. | $39.91 | 2025 | Nuzyra |
| Organon LLC | $29.82 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $24.65 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.92 | 2025 | Cabtreo |
| Sebela Pharmaceuticals INC. | $16.95 | 2022 | |
| Botanix Sb INC | $16.78 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $15.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omni Mccluney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.